%0 Generic %A Schutz, Charlotte %A Chirehwa, Maxwell %A Barr, David %A Ward, Amy %A Janssen, Saskia %A Burton, Rosie %A J. Wilkinson, Robert %A Shey, Muki %A Wiesner, Lubbe %A Denti, Paolo %A McIlleron, Helen %A Maartens, Gary %A Meintjes, Graeme %D 2019 %T Khayelitsha Hospital TB study pharmacokinetic variables: Non compartmental analysis %U https://zivahub.uct.ac.za/articles/dataset/Khayelitsha_Hospital_TB_study_pharmacokinetic_variables_Non_compartmental_analysis/9541991 %R 10.25375/uct.9541991.v1 %2 https://zivahub.uct.ac.za/ndownloader/files/17173031 %K HIV-TB %K pharmacokinetics parameters %K Clinical Pharmacology and Therapeutics %X
Human immunodeficiency virus associated tuberculosis (HIV-TB) comprise 10% of global tuberculosis cases but contribute a disproportionate 22% of global tuberculosis mortality. HIV-infected patients hospitalized with HIV-TB have high high case fatality rates despite treatment and often present with a clinical picture compatible with sepsis. There is paucity of data in critically ill HIV-infected patients admitted to hospital at the time of tuberculosis diagnosis. Improved, evidence-based treatment interventions in this patient group are urgently needed to improve survival.
We performed intensive pharmacokinetic studies (from 0-8 hours) in a high burden setting (Khayelitsha Hospital, Cape Town), within the routine service. We assessed rifampicin, isoniazid and pyrazinamide exposure in a group of hospitalized HIV-TB patients and a group of outpatients on the third day of standard antituberculosis therapy using non-compartmental analysis. We followed hospitalized patients for 12 weeks to asses survival. We compared pharmacokinetic exposures in hospitalized patients and outpatients; hospitalized patients who survived twelve weeks and those who died; and hospitalized patients presenting with high lactate (more than 2.2 mmol/L) and patient presenting with normal lactate.
%I University of Cape Town